Equity Details
Price & Market Data
Price: $5.19
Daily Change: +$0.02 / 0.39%
Daily Range: $5.04 - $5.89
Market Cap: $15,976,102
Daily Volume: 101,238
Performance Metrics
1 Week: -2.29%
1 Month: -7.40%
3 Months: -19.97%
6 Months: -54.40%
1 Year: -67.18%
YTD: -31.33%
About Cadrenal Therapeutics, Inc. (CVKD)
Daily market data for Cadrenal Therapeutics, Inc. (CVKD). Current price: 5.19, daily change: +$0.02 / 0.39%. Market cap: 15,976,102. Performance 1-week and 52-week.
Company Details
Employees: 5
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
